INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
Public company

LSTALISATA THERAPEUTICS, INC.

CIK 0000320017

EDGAR filingsOpen in network
Disclosed transactions19
Buys / sells0 / 0
Max Insider Score21
Connections5with evidence

LSTA · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
21
IT
Imam TariqSVP, Bus Dev, General Counsel
LSTALISATA THERAPEUTICS, INC.
Grant or award
A—
15.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 5, 2026
  • ← Insider ofevidence
    Imam TariqSVP, Bus Dev, General Counsel · Jan 13, 2026
  • ← Insider ofevidence
    Nisco JamesSVP, Fin/Treas, Chief Actg Off · Jan 13, 2026
  • ← Insider ofevidence
    Buck Kristen KEVP, R&D and CMO · Jan 13, 2026
9
IT
Imam TariqSVP, Bus Dev, General Counsel
LSTALISATA THERAPEUTICS, INC.
Tax withholding
F
$2,760
1,401 sh
Jan 9, 2026
Jan 13, 2026
traded Jan 9, 2026
+4d
SEC FORM 4

Evidence

9
IT
Imam TariqSVP, Bus Dev, General Counsel
LSTALISATA THERAPEUTICS, INC.
Tax withholding
F$1,655
840 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

9
IT
Imam TariqSVP, Bus Dev, General Counsel
LSTALISATA THERAPEUTICS, INC.
Tax withholding
F$1,472
747 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

9
IT
Imam TariqSVP, Bus Dev, General Counsel
LSTALISATA THERAPEUTICS, INC.
Tax withholding
F$1,011
513 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

9
IT
Imam TariqSVP, Bus Dev, General Counsel
LSTALISATA THERAPEUTICS, INC.
Grant or award
A—
7,000 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

21
NJ
Nisco JamesSVP, Fin/Treas, Chief Actg Off
LSTALISATA THERAPEUTICS, INC.
Grant or award
A—
15.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

13
NJ
Nisco JamesSVP, Fin/Treas, Chief Actg Off
LSTALISATA THERAPEUTICS, INC.
Tax withholding
F$4,198
2,131 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

13
NJ
Nisco JamesSVP, Fin/Treas, Chief Actg Off
LSTALISATA THERAPEUTICS, INC.
Tax withholding
F$4,198
2,131 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

9
NJ
Nisco JamesSVP, Fin/Treas, Chief Actg Off
LSTALISATA THERAPEUTICS, INC.
Tax withholding
F$2,240
1,137 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

9
NJ
Nisco JamesSVP, Fin/Treas, Chief Actg Off
LSTALISATA THERAPEUTICS, INC.
Tax withholding
F$1,539
781 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

9
NJ
Nisco JamesSVP, Fin/Treas, Chief Actg Off
LSTALISATA THERAPEUTICS, INC.
Grant or award
A—
7,000 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

17
BK
Buck Kristen KEVP, R&D and CMO
LSTALISATA THERAPEUTICS, INC.
Grant or award
A—
25.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

9
BK
Buck Kristen KEVP, R&D and CMO
LSTALISATA THERAPEUTICS, INC.
Tax withholding
F$5,875
2,982 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

9
BK
Buck Kristen KEVP, R&D and CMO
LSTALISATA THERAPEUTICS, INC.
Tax withholding
F$5,875
2,982 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

9
BK
Buck Kristen KEVP, R&D and CMO
LSTALISATA THERAPEUTICS, INC.
Tax withholding
F$6,345
3,221 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

9
BK
Buck Kristen KEVP, R&D and CMO
LSTALISATA THERAPEUTICS, INC.
Tax withholding
F$4,230
2,147 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

9
BK
Buck Kristen KEVP, R&D and CMO
LSTALISATA THERAPEUTICS, INC.
Grant or award
A—
13.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

17
FL
Flowers Cynthia LouiseDirector
LSTALISATA THERAPEUTICS, INC.
Grant or award
A—
30.5K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Flowers Cynthia LouiseDirector · Jan 13, 2026